Clinical and haemostatic effects of intravenous prostaglandin E1 therapy in patients with peripheral arterial occlusive disease

Panminerva Medica

Volumn 41, Issue 1, 1999, Pages 15-17

  Trifiletti, A ^a   Scamardi, R ^a   Pizzoleo, M A ^a   Sottilotta, G ^a   Soraci, S ^a   Attina A ^a   Bagnato, L ^a   Barbera, N ^a  

^a NONE

Author keywords

Alprostadil; Arterial occlusive disease; Blood coagulation

Indexed keywords

PROSTAGLANDIN E1;

AGED; ARTICLE; CLINICAL TRIAL; FEMALE; HEMOSTASIS; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; MIDDLE AGED; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PHYSIOLOGY;

AGED; ALPROSTADIL; ARTERIAL OCCLUSIVE DISEASES; FEMALE; HEMOSTASIS; HUMANS; INJECTIONS, INTRAVENOUS; MALE; MIDDLE AGED;

EID: 0033090984     PISSN: 00310808     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (12)

1. Criqui MH, Langer RD, Fronek A, Fegelson HS, Klauber MR, MacCann TJ et al. Mortality over a period of 10 years in patients with peripheral arterial disease. N Engl J Med 1992;326:381-6.
2. Dormandy J, Mahir M, Ascady G, Balsano F, De Leeuw P, Blombery P et al. Fate of the patients with chronic leg ischemia. J Cardiovasc Surg 1989;30:50-7.
3. Cortellaro M, Boschetti C, Cofrancesco E, Musconi L, Donati MB, Cardillo M et al. The PLAT study: a multidisciplinary study of hemostatic function and conventional risk factors in vascular disease patients. Atherosclerosis 1991;90:109-18.
4. Cortellaro M, Cofrancesco E, Boschetti C, Musconi L, Donati MB, Cardillo M et al. Case-control study of fibrinolytic variables as predictors of ischemic events in atherosclerotic patients enrolled in the PLAT study. XIVth Congress of the International Society on Thrombosis and Haemostasis, New York, July 4-9, 1993.
5. Cofrancesco E, Cortellaro M, Boschetti C, Musconi L, Donati MB, Cardillo M et al. Fibrinolytic variables in atherosclerotic patients; comparison between patients with and without peripheral arterial disease (PAD). XIVth Congress of the International Society on Thrombosis and Haemostasis, New York, July 4-9, 1993.
6. Trifiletti A, Barbera N, Pizzoleo MA, Leone G, Lucifora S, Soraci S et al. Hemostatic disorders associated with arterial hypertension and peripheral arterial disease. J Cardiovasc Surg 1995;36(5):483-5.
7. Schror K. Prostaglandine und verwandte Substanzen. Stuttgart: Thieme, 1984.
8. Rudofsky G. Beeinflussung der Kollateralarterien durch e. a. Prostaglandin E1-Infusion. VASA 1987;20(Suppl):215.
9. Rudofsky G. The effect of intra-arterial and intravenous prostaglandin E1 in a model of ischemia in healthy volunteers. In: Sinzinger H, Rogatti W, editors. Prostaglandin E1 in atherosclerosis. Berlin: Springer Verlag, 1986:49-53.
10. Fantone JC, Kunkel SL, Ward PA, Zurier RB. Suppression of human polymorphonucleur leukocyte function after intravenous infusion of prostaglandine E1. Prostagtandins Med 1981;2:195-8.
11. Ney P, Schror K. E-type proslaglandins but not iloprost inhibit platelet activating factor-induced generation of leukotriene B4 by human polymorphonuclear leukocytes. Br J Pharmacol 1989;96:186-92.
12. Stiegter H, Rett K, Wieklmayr M, Mehnert H. Metabolic effects of prostaglandin E1 on human skeletat muscle with special regard to the amino acid metabolism. VASA 1989;28(Suppl):14-8.